‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients.

Link to article at PubMed

Related Articles

'Primed' Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients.

Stem Cell Rev Rep. 2020 Jun 26;:

Authors: Raza SS, Seth P, Khan MA

Abstract
The COVID19 pandemic, designated as a public health crisis by the World Health Organization (WHO), is rapidly spreading around the world impacting the health and economy of almost all the countries. The data of hospitalized COVID19 patients, especially those with serious illness, indicate the involvement of immunopathological complications. As no effective treatment is currently available, we propose 'Primed' Mesenchymal Stem Cells (MSCs) as a therapeutic alternative to tackle devastating epidemic. The individual response to MSCs treatment is heterogeneous. During the treatment of infectious pathology, the effectiveness of the treatment may vary based on the disease scenario. Interestingly, when transplanted in vivo, MSCs are governed by the locally regulated microenvironment, suggesting that the restorative variability could be tailored by choosing a priming regimen to specifically correct a given pathology. Therefore, in our opinion, the priming of MSCs could be a novel approach to improve the responses of COVID19 patients.

PMID: 32592163 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.